PMID- 38524063
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240326
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Electronic)
IS  - 2168-8184 (Linking)
VI  - 16
IP  - 2
DP  - 2024 Feb
TI  - Fulminant Myocarditis and Venoarterial Extracorporeal Membrane Oxygenation: A 
      Systematic Review.
PG  - e54711
LID - 10.7759/cureus.54711 [doi]
LID - e54711
AB  - This systematic review aimed to look at the effectiveness of venoarterial 
      extracorporeal membrane oxygenation (VA-ECMO) therapy in treating fulminant 
      myocarditis and evaluating the optimal length of time a patient should be placed 
      on VA-ECMO. Fulminant myocarditis is a potentially life-threatening medical 
      condition most commonly brought on by cardiogenic shock, which often progresses 
      to severe circulatory compromise, requiring the patient to be placed on some form 
      of mechanical circulatory assistance to maintain adequate tissue perfusion. 
      Medical centers have multiple mechanical assistive devices available for 
      treatment at their disposal, but our area of focus was placed on one system in 
      particular: VA-ECMO therapy. Although the technology has been around for more 
      than 30 years, there is limited information on how effective VA-ECMO is regarding 
      the treatment of fulminant myocarditis. Due to the lack of data regarding the 
      treatment administration of VA-ECMO for fulminant myocarditis, standard treatment 
      duration guidelines do not exist, resulting in a wide variation of treatment 
      administrations among medical centers. In regard to short-term outcomes, VA-ECMO 
      has shown to be effective in treating fulminant myocarditis, with a one-year 
      post-hospital survival rate ranging from 57.1% to 78% at discharge. For long-term 
      health and survival, the studies that recorded long-term survival ranged from 65% 
      to 94.1%. However, given the small number of studies that pursue this, more 
      research is needed to prove the efficacy of VA-ECMO for the treatment of 
      fulminant myocarditis.
CI  - Copyright (c) 2024, Briglio et al.
FAU - Briglio, Spencer E
AU  - Briglio SE
AD  - Anatomical Sciences, St. George's University School of Medicine, True Blue, GRD.
FAU - Khanduja, Viraj
AU  - Khanduja V
AD  - Anatomical Sciences, St. George's University School of Medicine, True Blue, GRD.
FAU - Lothan, Justin D
AU  - Lothan JD
AD  - Anatomy, St. George's University, True Blue, GRD.
FAU - Gorantla, Vasavi Rakesh
AU  - Gorantla VR
AD  - Anatomical Sciences, St. George's University, True Blue, GRD.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20240222
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC10960644
OTO - NOTNLM
OT  - cardiogenic shock
OT  - fulminant myocarditis
OT  - left ventricular ejection fraction
OT  - mechanical circulatory assistance
OT  - venoarterial extracorporeal membrane oxygenation
COIS- The authors have declared that no competing interests exist.
EDAT- 2024/03/25 06:42
MHDA- 2024/03/25 06:43
PMCR- 2024/02/22
CRDT- 2024/03/25 04:21
PHST- 2024/02/22 00:00 [accepted]
PHST- 2024/03/25 06:43 [medline]
PHST- 2024/03/25 06:42 [pubmed]
PHST- 2024/03/25 04:21 [entrez]
PHST- 2024/02/22 00:00 [pmc-release]
AID - 10.7759/cureus.54711 [doi]
PST - epublish
SO  - Cureus. 2024 Feb 22;16(2):e54711. doi: 10.7759/cureus.54711. eCollection 2024 
      Feb.